Corsidus provides an “Advancement” program service to scientific researches and academicians whereby a select and cost-effective array of preclinical pharmacology, safety and toxicology studies are chosen to qualify the feasibility of a discovery drug to advance further in development and become a clinical candidate. This service will provide sufficient early preclinical data to establish a baseline assessment of a drug’s development potential.

The “Advancement” program is tailored to each client’s specific needs, budgets and resource allocations and is strategically aligned with customer short-term development objectives.

The “Advancement” program may also be focused to gain the interest of potential investors. Data are prepared to the highest scientific and regulatory standards for clients to present to interested third parties for sale, licensing or partnering opportunities.

Corsidus Program Management

Corsidus Program Management can maximize your efficiencies by tailoring an overall strategic and tactical drug development plan that is flexible and responsive to your needs.

Corsidus can provide early drug developers with pharmaceutical guidance strategies that minimize cost and maximize information through targeted studies with highly focused objectives.

Corsidus can guide you through the various AMS and PET microdose study options depending on your class of drug and therapeutic objective.

Corsidus will provide data management services ensuring that final study reports will be in an approved format consistent with current eIND and IND submission packages.